Stock Spotlights Archives - Page 7 of 19

MondayJul 03, 2023 12:29 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Adds Greater Flexibility, Accelerated Technology Development Capability to NVIDIA Omniverse Platform

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, recently integrated its Vista-X120 Plus lidar into DRIVE Sim, an end-to-end simulation application built on the NVIDIA Omniverse platform. “The NVIDIA Omniverse platform enables real-time simulation and 3D visualization for metaverse applications by providing a shared virtual environment where users can collaborate to engineer real-world scenarios… Cepton was one of the first companies to demonstrate a 360°-coverage, dual-range lidar simulation that detected long-range obstacles and eliminated near-range blind spots. The addition of the Vista-X120 Plus into the Omniverse builds upon previous integrations to give AV developers access…

MondayJul 03, 2023 12:08 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL…

FridayJun 16, 2023 2:25 pm

TinyGemsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC,” a recent article explains. “During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One…

FridayJun 09, 2023 10:38 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. “The new patents will add to Lexaria’s growing portfolio and, upon award, will bring the total number of patents granted worldwide to 32, with several more pending,” a recent article reads. “Lexaria’s new patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Agents. This patent is the fifth awarded in Japan, strengthening the company’s growing…

MondayMay 22, 2023 12:40 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Overcoming Primary Barriers to Commercialization of Lidar for ADAS

Cepton (NASDAQ: CPTN) is commercializing lidar systems for autonomous vehicles and advanced driver-assistance systems (“ADAS”) as well as developing solutions for a range of other industries. “Commercialization of lidar for ADAS faces two primary obstacles: perception capabilities and sensor embeddability into modern vehicle designs. Lidar pioneer Cepton’s Ultra-Slim Vista(R) Plus lidar overcomes both barriers while setting new industry standards. Billed by CPTN as the ‘world’s smallest’ adaptive long-range lidar, the Vista-X90 Plus is 62% slimmer than its predecessor – the Vista(R)-X90 – with a 58% footprint reduction. Besides offering an extremely streamlined solution for windshield integration, the Vista-X90 Plus can…

FridayApr 21, 2023 1:46 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, the study will also enroll patients who have received additional treatments as part of the first-line therapy in recognition of the complexity of new agents introduced as a component of this therapy. The study will compare Berubicin, a novel anthracycline and the first anthracycline to…

FridayApr 21, 2023 12:45 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Differentiated with Focus on Tech-Driven Solutions, Outstanding Customer Service

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) recently acknowledged an endorsement by leading investment and research firm Chardan Capital Research that included a buy rating for the company at a price target of $2.00. “We are pleased to be able to share the results of Chardan’s independent analysis of our company’s growth and potential. Our focus on technology-driven solutions and outstanding customer service has allowed us to differentiate ourselves in the market, and we will continue to build on that success,” a recent article quotes Fr8Tech CEO Javier Selgas as saying. “Fr8Tech has built a suite of technology-based solutions to help automate…

FridayApr 14, 2023 12:52 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability of and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM). “Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (‘CBD’), aligned with other study work pointing to…

FridayMar 24, 2023 12:33 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected.…

WednesdayMar 22, 2023 11:00 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Continued Growth in Cross-Border and Domestic FTL Offerings

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, is dedicated to keeping freight moving around the country and between the United States’ primary land-based trading partners in an efficiently designed and successful manner. The company does this using its flagship AI-powered Fr8App B2B marketplace as a powerful tool. “Fr8Tech recently announced its market guidance data, projecting revenues of between $36 million and $42 million for 2023, which will be an increase over 2022’s preliminary revenue figures of approximately $26 million to $27 million. The company’s projections for revenue growth are underscored by the comments President Biden made during…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: Stock Spotlights